CytoDyn (STU:296) E10: €0.00 (As of Feb. 2026)


STU:296 CytoDyn Inc STU:296
28 GF Score
Price €0.20
! 1 Warning Sign
View Full Analysis

What is CytoDyn E10?

CytoDyn STU:296 +3.13% 28 E10 is €0.00 as of Feb. 2026. GuruFocus rates STU:296 with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

CytoDyn's adjusted earnings per share data for the three months ended in Feb. 2026 was €0.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Feb. 2026.

During the past 3 years, the average E10 Growth Rate was 8.30% per year. During the past 5 years, the average E10 Growth Rate was 2.20% per year. During the past 10 years, the average E10 Growth Rate was -0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of CytoDyn was 8.30% per year. The lowest was -8.00% per year. And the median was -2.65% per year.

As of today (2026-07-04), CytoDyn's current stock price is €0.198. CytoDyn's E10 for the quarter that ended in Feb. 2026 was €0.00. CytoDyn's Shiller PE Ratio of today is .


CytoDyn  (STU:296) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


CytoDyn E10 Related Terms


CytoDyn E10 Historical Data

* Premium members only.

The historical data trend for CytoDyn's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CytoDyn E10 Chart

CytoDyn Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.33 -0.30 -0.40 -0.24

CytoDyn Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.24 0.00 -0.19 0.00

STU:296 vs VSTM, IRD, PALI: E10 Comparison

For the Biotechnology subindustry, CytoDyn's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CytoDyn Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where CytoDyn's Shiller PE Ratio falls into.


STU:296
28GF Score
CytoDyn Inc STU:296
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, CytoDyn's adjusted earnings per share data for the three months ended in Feb. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Feb. 2026 (Change)*Current CPI (Feb. 2026)
=0/326.7850*326.7850
=0.000

Current CPI (Feb. 2026) = 326.7850.

CytoDyn Quarterly Data

per share eps CPI Adj_EPS
201605 -0.044 240.229 -0.060
201608 -0.036 240.849 -0.049
201611 -0.037 241.353 -0.050
201702 -0.056 243.603 -0.075
201705 -0.045 244.733 -0.060
201708 -0.068 245.519 -0.091
201711 -0.060 246.669 -0.079
201802 -0.081 248.991 -0.106
201805 -0.034 251.588 -0.044
201808 -0.061 252.146 -0.079
201811 -0.053 252.038 -0.069
201902 -0.035 252.776 -0.045
201905 -0.045 256.092 -0.057
201908 -0.036 256.558 -0.046
201911 -0.036 257.208 -0.046
202002 -0.073 258.678 -0.092
202005 -0.147 256.394 -0.187
202008 -0.051 259.918 -0.064
202011 -0.051 260.229 -0.064
202102 -0.066 263.014 -0.082
202105 -0.091 269.195 -0.110
202108 -0.060 273.567 -0.072
202111 -0.053 277.948 -0.062
202202 -0.053 283.716 -0.061
202205 -0.114 292.296 -0.127
202208 -0.030 296.171 -0.033
202211 -0.029 297.711 -0.032
202302 -0.019 300.840 -0.021
202305 -0.018 304.127 -0.019
202308 -0.009 307.026 -0.010
202311 -0.009 307.051 -0.010
202402 -0.009 310.326 -0.009
202405 -0.009 314.069 -0.009
202408 0.018 314.796 0.019
202411 0.000 315.493 0.000
202502 0.000 319.082 0.000
202505 -0.009 321.465 -0.009
202508 0.000 323.976 0.000
202511 -0.017 324.122 -0.017
202602 0.000 326.785 0.000

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
CytoDyn (STU:296) has a E10 of €0.00 as of Feb. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CytoDyn and its competitors.
Is CytoDyn's E10 too high?
CytoDyn's current E10 is €0.00. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's E10 compare to VSTM and IRD?
CytoDyn's E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on CytoDyn and its competitors. CytoDyn's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (STU:296) has a current E10 of €0.00. The current E10 is €0.00. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For CytoDyn (STU:296), the current E10 is €0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges CYDY:USA
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for STU:296

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.20
Price